Open AccessA surrogate marker for Aβ42 production in the CNS
Author(s) -
Holtzman David M.
Publication year - 2009
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.1002/emmm.200900030
Subject(s) - surrogate endpoint , production (economics) , medicine , economics , macroeconomics
Alzheimer's disease (AD) is the most common cause of dementia. There are currently no effective treatments that may delay the onset, slow the progression or prevent the disease. Unless such treatments are developed, the number of AD cases is expected to double in the next 30 years. There is overwhelming genetic and biochemical evidence that the aggregation and buildup of the amyloid‐β (Aβ) peptide plays a critical role in AD pathogenesis.